Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders

Authors

  • Enrico Galmozzi Ph.D.,

    1. First Division of Gastroenterology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Università degli Studi di Milano Milan, Italy
    Search for more papers by this author
  • Alessio Aghemo M.D.,

    1. First Division of Gastroenterology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Università degli Studi di Milano Milan, Italy
    Search for more papers by this author
  • Massimo Colombo M.D.

    1. First Division of Gastroenterology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Università degli Studi di Milano Milan, Italy
    Search for more papers by this author

  • Potential conflicts of interest: Alessio Aghemo, M.D.: Grant and research support: Roche, Gilead Sciences; Speaking and Teaching: Roche, Janssen; Travel support: BMS, Glaxo Smith-Kline, Bayer, Janssen, Roche. Massimo Colombo, M.D.: Grant and research support: Merck, Roche, BMS, Gilead Science; Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibotec, Vertex, Achillion; Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science, Vertex. Enrico Galmozzi, Ph.D., has nothing to disclose.

No abstract is available for this article.

Ancillary